The store will not work correctly when cookies are disabled.
5-(benzyloxy)-N-(2-chlorophenyl)pyrazolo[1,5-a]pyridine-3-carboxamide
ID: ALA1078726
PubChem CID: 46882659
Max Phase: Preclinical
Molecular Formula: C21H16ClN3O2
Molecular Weight: 377.83
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(Nc1ccccc1Cl)c1cnn2ccc(OCc3ccccc3)cc12
Standard InChI: InChI=1S/C21H16ClN3O2/c22-18-8-4-5-9-19(18)24-21(26)17-13-23-25-11-10-16(12-20(17)25)27-14-15-6-2-1-3-7-15/h1-13H,14H2,(H,24,26)
Standard InChI Key: UYOQRNSCWIITKH-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 30 0 0 0 0 0 0 0 0999 V2000
9.7527 -0.2833 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.7516 -1.1107 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.4664 -1.5235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.4646 0.1295 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.1800 -0.2797 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.1802 -1.1107 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.9707 -1.3673 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.4590 -0.6948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.9707 -0.0216 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.9857 0.8033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7075 1.2027 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.2788 1.2287 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.2938 2.0536 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.0203 2.4497 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.0356 3.2737 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3305 3.6928 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6040 3.2962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.5922 2.4734 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.8716 2.0716 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
9.0382 0.1290 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.3238 -0.2836 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.6092 0.1287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.6127 0.9543 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8990 1.3665 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1836 0.9538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1865 0.1245 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.9008 -0.2840 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12 13 1 0
3 6 1 0
13 14 2 0
1 2 1 0
14 15 1 0
5 4 1 0
15 16 2 0
6 7 1 0
16 17 1 0
7 8 2 0
17 18 2 0
18 13 1 0
8 9 1 0
18 19 1 0
9 5 2 0
1 20 1 0
4 1 2 0
20 21 1 0
9 10 1 0
21 22 1 0
5 6 1 0
22 23 2 0
10 11 2 0
23 24 1 0
24 25 2 0
10 12 1 0
25 26 1 0
2 3 2 0
26 27 2 0
27 22 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 377.83 | Molecular Weight (Monoisotopic): 377.0931 | AlogP: 4.82 | #Rotatable Bonds: 5 |
Polar Surface Area: 55.63 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 0.78 | CX LogP: 4.77 | CX LogD: 4.77 |
Aromatic Rings: 4 | Heavy Atoms: 27 | QED Weighted: 0.54 | Np Likeness Score: -1.68 |
References
1. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD.. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors., 19 (21): [PMID:19783434] [10.1016/j.bmcl.2009.09.010] |